NCT02914171View on ClinicalTrials.gov

Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

March 18, 2021

Study Completion Date

March 18, 2021

Conditions
Ebstein Anomaly
Interventions
BIOLOGICAL

Autologous Bone Marrow-derived Mononuclear Cells

DEVICE

Insertable cardiac monitor

Following surgical Ebstein repair a Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) will be placed subcutaneously in the anterior chest to continuously monitor the subject's heart rhythm and to record cardiac information through automatic detection of arrhythmias.

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

Timothy J. Nelson

OTHER

NCT02914171 - Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly | Biotech Hunter | Biotech Hunter